SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma

Hedner, Charlotta; Gaber, Alexander; Korkocic, Dejan; Nodin, Björn; Uhlén, Mathias; Kuteeva, Eugenia; Johannesson, Henrik; Jirström, Karin; Eberhard, Jakob

doi:10.1007/s00428-014-1667-6

Cited by 26 publications

(29 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Annotation of the absolute percentage of positively stained cells was multiplied by the annotated intensity (scored 0-3) of stained cells, and a mean expression score was subsequently calculated for each patient at each time point. This method was validated earlier (14)(15)(16). Discrepant cores were discussed until consensus was reached.…”

Section: Methodsmentioning

confidence: 99%

MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer

Stene

Polistena

Gaber

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer

Stene

Polistena

Gaber

et al. 2018

View full text Add to dashboard Cite

show abstract

“…SATB1 can regulate the expression of >1,000 genes involved in the processes of DNA organization, proliferation and apoptosis (8,9). SATB1 has been demonstrated to serve roles in malignancies, in addition to malignant transformation (7,20).…”

Section: Introductionmentioning

confidence: 99%

“…SATB1 can regulate gene expression by folding chromatin into loop domains and tethering DNA domains to the SATB1 network structure (7,8). Under normal conditions, SATB1 is expressed at low levels in cells and tissues, but is overexpressed in a variety of malignant tumors, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular carcinoma, rectal cancer, cutaneous malignant melanoma, gastric cancer, prostate cancer, lung cancer and cutaneous T-cell lymphoma (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The expression of SATB1 has been examined in esophageal adenocarcinoma and is an independent prognostic factor (20).…”

Section: Introductionmentioning

confidence: 99%

“…Under normal conditions, SATB1 is expressed at low levels in cells and tissues, but is overexpressed in a variety of malignant tumors, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular carcinoma, rectal cancer, cutaneous malignant melanoma, gastric cancer, prostate cancer, lung cancer and cutaneous T-cell lymphoma (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The expression of SATB1 has been examined in esophageal adenocarcinoma and is an independent prognostic factor (20). In several types of cancer, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular cancer and lung cancer, high expression of SATB1 promotes tumor growth and metastasis, and is a negative prognostic factor (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

“…The expression of SATB1 has been examined in esophageal adenocarcinoma and is an independent prognostic factor (20). In several types of cancer, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular cancer and lung cancer, high expression of SATB1 promotes tumor growth and metastasis, and is a negative prognostic factor (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). SATB1 can regulate the expression of >1,000 genes involved in the processes of DNA organization, proliferation and apoptosis (8,9).…”

mentioning

confidence: 99%

See 2 more Smart Citations

High expression of special AT‑rich sequence binding protein‑1 predicts esophageal squamous cell carcinoma relapse and poor prognosis

et al. 2017

View full text Add to dashboard Cite

Abstract. Previous studies of the roles of special AT-rich sequence binding protein-1 (SATB1) in the development and progression of cancer have suggested that SATB1 promotes cancer cell metastasis. The aim of the present study is to evaluate the role of SATB1 in the progression and prognosis of esophageal squamous cell carcinoma (ESCC). ESCC tissues were collected from 102 patients and SATB1 mRNA expression was measured by reverse transcription-quantitative polymerase chain reaction. The association between expression of SATB1 mRNA with clinicopathological features and prognosis was assessed, and the prognosis of ESCC was evaluated using Kaplan-Meier survival curves. In the 102 ESCC tissues, SATB1 mRNA expression correlated with the clinical tumor node metastasis stage (P<0.05), but not with any other clinicopathological features (including age, gender, tumor differentiation grade, adjuvant radio/chemotherapy, or the consumption of alcohol and use of cigarettes) (P>0.05). The disease-free survival (DFS) and overall survival (OS) of patients with high SATB1 expression was decreased compared with those with low SATB1 expression. The present study indicated that SATB1 mRNA expression was associated with the postoperative recurrent and poor prognosis in ESCC. SATB1 may be a novel marker for predicting the recurrent and worse prognosis of ESCC. IntroductionEsophageal cancer cases are distributed worldwide; its mortality rate ranks sixth among all types of cancer and it is the fourth most commonly occurring cancer in China (1,2). China is among the highest risk areas of esophageal cancer, where ~90% of cases are squamous cell carcinoma (SCC) (3). The 5-year survival rate and quality of life remain low (3). However, the molecular mechanisms underlying the initiation and progression of esophageal SCC (ESCC) remain unclear.Special AT-rich sequence binding protein-1 (SATB1), a tissue-specific nuclear matrix binding protein, was identified in 1992 (4). SATB1 is primarily expressed in thymocytes, and also the expression of SATB1 in the basal layer of the epidermis is regulated by p63 (5,6). SATB1 can regulate gene expression by folding chromatin into loop domains and tethering DNA domains to the SATB1 network structure (7,8). Under normal conditions, SATB1 is expressed at low levels in cells and tissues, but is overexpressed in a variety of malignant tumors, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular carcinoma, rectal cancer, cutaneous malignant melanoma, gastric cancer, prostate cancer, lung cancer and cutaneous T-cell lymphoma (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The expression of SATB1 has been examined in esophageal adenocarcinoma and is an independent prognostic factor (20). In several types of cancer, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular cancer and lung cancer, high expression of SATB1 promotes tumor growth and metastasis, and is a negative prognostic factor (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). SATB1 can regul...

show abstract

SATB1 3′‐UTR and lncRNA‐UCA1 competitively bind to miR‐495‐3p and together regulate the proliferation and invasion of gastric cancer

Sun

Liu

Yang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

High expression of special AT‐rich‐binding protein 1 (SATB1) correlates with the advanced TNM stage and short overall and recurrence‐free survival of gastric cancer (GC). A bioinformatic analysis revealed that SATB1 3′‐untranslated region (3′‐UTR) and long noncoding RNA UCA1 (lncRNA‐UCA1) might competitively bind to microRNA‐495‐3p (miR‐495‐3p). Interestingly, lncRNA‐UCA1 is also an important contributor to GC. The current study aimed to demonstrate the potential interaction among SATB1/miR‐495‐3p/lncRNA‐UCA1 network and their effects on GC proliferation and invasion. The expression in GC and paracancerous normal tissues were assessed using real‐time polymerase chain reaction and Western blot analysis. Luciferase reporter, RNA pull‐down, and transfection assays were performed to determine the interaction among SATB1/miR‐495‐3p/lncRNA‐UCA1 network in GC cells. GC proliferation and invasion were evaluated using 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide, transwell invasion, and colony formation assays. Results showed higher expression of SATB1 and lncRNA‐UCA1 but lower miR‐495‐3p expression in GC than in the normal tissues. In luciferase reporter assay, miR‐495‐3p bound to three seed sequences in SATB1 3′‐UTR but only one in lncRNA‐UCA1. SATB1 knockdown increased the combination of miR‐495‐3p with lncRNA‐UCA1 but decreased lncRNA‐UCA1 expression. Decreased lncRNA‐UCA1 was also observed with the mimics increased miR‐495‐3p. These data suggested that SATB1 3′‐UTR functions as a competing endogenous RNA of miR‐495‐3p and positively regulates lncRNA‐UCA1. LncRNA‐UCA1 knockdown only decreased SATB1 expression in MKN‐45 cells but not in BGC‐823 cells, which suggested that the regulatory effect of lncRNA‐UCA1 on SATB1 by sponging miR‐495‐3p is cell‐dependent. This study further identified that SATB1/miR‐495‐3p/lncRNA‐UCA1 network is implicated in GC proliferation and invasion. The current study firstly revealed that SATB1 interacts with miR‐495‐3p/lncRNA‐UCA1 network, whereby enhancing GC proliferation and invasion.

show abstract

SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma

Cited by 26 publications

References 35 publications

MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer

MMP7 Modulation by Short- and Long-term Radiotherapy in Patients with Rectal Cancer

High expression of special AT‑rich sequence binding protein‑1 predicts esophageal squamous cell carcinoma relapse and poor prognosis

SATB1 3′‐UTR and lncRNA‐UCA1 competitively bind to miR‐495‐3p and together regulate the proliferation and invasion of gastric cancer

Contact Info

Product

Resources

About